# MOLECULAR CANCER THERAPEUTICS

## TABLE OF CONTENTS

### HIGHLIGHTS

1221  
**Selected Articles from This Issue**

### REVIEW

1223  
**In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL**  
Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani, and Roddy S. O’Connor

### SMALL MOLECULE THERAPEUTICS

1234  
**Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis**  
Anu Gupta, Jarnail Singh, Alfonso García-Valverde, César Serrano, Daniel L. Flynn, and Bryan D. Smith

1246  
**Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma**  
Brent A. Willobee, Alexander A. Gaidarski, Austin R. Dosch, Jason A. Castellanos, Xizi Dai, Siddharth Mehra, Fanuel Messaggio, Supriya Srinivasan, Michael N. VanSaun, Nagaraj S. Nagathihalli, and Nipun B. Merchant

1257  
**Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress**  

### LARGE MOLECULE THERAPEUTICS

1270  
**PCA062, a P-cadherin Targeting Antibody–Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin–expressing Malignancies**  

1283  
**Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells**  
Mariko Ishibashi, Junichi Yamamoto, Takumi Ito, Hiroshi Handa, Mika Sunakawa-Kii, Koiti Inokuchi, Rimpei Morita, and Hideto Tamura

1295  
**Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti–PD-L1 Immunotherapy**  
Bin Yi, Hao Cheng, Dorota Wyczewska, Qingzhao Yu, Li Li, Augusto C. Ochoa, Adam I. Riker, and Yaguang Xi
TARGETING DRUG RESISTANCE

1305  Blocking Wnt/β-catenin Signal Amplifies Anti-PD-1 Therapeutic Efficacy by Inhibiting Tumor Growth, Migration, and Promoting Immune Infiltration in Glioblastomas
Hui Zhang, Yongyan Bi, Yuxi Wei, Jiayang Liu, Kudelaidi Kuerban, and Li Ye

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

1316  BRAF V600E Mutation in Cell-Free DNA, Rather than in Lesion Tissues, at Diagnosis Is An Independent Prognostic Factor in Children with Langerhans Cell Histiocytosis
Chan-Juan Wang, Lei Cui, Hong-Hao Ma, Dong Wang, Li Zhang, Hong-Yun Lian, Wei-Jing Li, Qing Zhang, Tian-You Wang, Zhi-Gang Li, and Rui Zhang

ABOUT THE COVER

Close-up view of the binding interface between PCA062 (light cyan/violet ribbon), a therapeutic antibody drug conjugate and its target protein antigen, human P-cadherin (gold ribbon), a cell surface glycoprotein highly expressed in several human malignancies. Glutamate E155, a central epitope residue, is unique to human P-cadherin, thus conferring this antibody exquisite selectivity in delivering its toxic payload to P-cadherin expressing cancer cells. Read the full manuscript by Sheng and colleagues on page 1270.

AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org